Inventiva (IVA) News Today $2.64 -0.10 (-3.65%) (As of 10:15 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Inventiva Prepares for Key General Meeting and Financing PlansNovember 21 at 2:24 AM | markets.businessinsider.comInventiva Reports Voting Rights and Advances Clinical TrialsNovember 21 at 2:24 AM | markets.businessinsider.comCombined General Meeting of December 11, 2024 - Availability of the preparatory documentsNovember 20 at 4:00 PM | globenewswire.comThe first MASH drug could open the door for others — including GLP-1sNovember 18 at 8:54 AM | finance.yahoo.comInventiva (NASDAQ:IVA) Now Covered by Analysts at UBS GroupNovember 16, 2024 | americanbankingnews.comInventiva’s Phase 2 Results Boost Hope for MASH TreatmentNovember 15, 2024 | markets.businessinsider.comInventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker sessionNovember 15, 2024 | globenewswire.comInventiva S.A. Plans Key Shareholder Meeting in DecemberNovember 15, 2024 | markets.businessinsider.comCautious Optimism for Inventiva’s Lanifibranor Amidst Execution Challenges and Dilution RisksNovember 13, 2024 | markets.businessinsider.comInventiva initiated with a Neutral at UBSNovember 13, 2024 | markets.businessinsider.comInventiva (NASDAQ:IVA) Coverage Initiated by Analysts at UBS GroupUBS Group began coverage on Inventiva in a research report on Tuesday. They set a "neutral" rating and a $3.00 price target for the company.November 12, 2024 | marketbeat.comInventiva Gains Positive Nod for Lanifibranor TrialOctober 31, 2024 | markets.businessinsider.comInventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASHOctober 30, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Short Interest UpdateInventiva S.A. (NASDAQ:IVA - Get Free Report) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 853,400 shares, an increase of 562.1% from the September 30th total of 128,900 shares. Based on an average daily trading volume, of 201,000 shares, the days-to-cover ratio is presently 4.2 days.October 25, 2024 | marketbeat.comInventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024October 21, 2024 | globenewswire.comFY2026 EPS Forecast for Inventiva Increased by AnalystInventiva S.A. (NASDAQ:IVA - Free Report) - Equities researchers at HC Wainwright raised their FY2026 earnings per share estimates for Inventiva in a note issued to investors on Tuesday, October 15th. HC Wainwright analyst E. Arce now expects that the company will earn ($2.43) per share for the yOctober 18, 2024 | marketbeat.comInventiva Secures €348 Million Financing, Reinforcing Buy Rating Amid Strategic AdvancementsOctober 16, 2024 | markets.businessinsider.comInventiva Shares Surge In Pre-market After Securing Finance To Advance NATiV3 Phase 3 MASH StudyOctober 14, 2024 | markets.businessinsider.comWhy Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?October 14, 2024 | finance.yahoo.comInventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrantsOctober 14, 2024 | globenewswire.comInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportOctober 14, 2024 | finance.yahoo.comInventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportOctober 14, 2024 | globenewswire.comInventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH studyOctober 14, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)September 29, 2024 | markets.businessinsider.comInventiva (NASDAQ:IVA) Stock Quotes, Forecast and News SummarySeptember 28, 2024 | benzinga.comInventiva (NASDAQ:IVA) Given New $14.00 Price Target at HC WainwrightHC Wainwright cut their target price on shares of Inventiva from $22.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday.September 26, 2024 | marketbeat.comINVENTIVA: Inventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsSeptember 25, 2024 | finanznachrichten.deInventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsSeptember 25, 2024 | globenewswire.comGH Research PLC (1KA.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (BX2.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comEarnings week ahead: Micron, Costco, BlackBerry, Accenture and moreSeptember 22, 2024 | msn.comAkero Therapeutics: Good Candidate For The MASH BasketSeptember 20, 2024 | seekingalpha.comInventiva (NASDAQ:IVA) Trading Down 5.2%Inventiva (NASDAQ:IVA) Stock Price Down 5.2%August 31, 2024 | marketbeat.comStifel Nicolaus Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)August 15, 2024 | markets.businessinsider.comINVENTIVA: Inventiva Reports Preliminary 2024 First-Half Financial InformationAugust 1, 2024 | finanznachrichten.deInventiva Reports Preliminary 2024 First-Half Financial Information¹July 31, 2024 | globenewswire.comINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | finanznachrichten.deInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25, 2024 | globenewswire.comINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | finanznachrichten.deHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJuly 19, 2024 | globenewswire.comInventiva announces a €20.1 million issuance of royalty certificatesJuly 18, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Sees Large Growth in Short InterestInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 130,800 shares, an increase of 12.6% from the June 15th total of 116,200 shares. Based on an average daily trading volume, of 15,000 shares, the days-to-cover ratio is currently 8.7 days.July 17, 2024 | marketbeat.comInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionJuly 5, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Given Average Recommendation of "Buy" by AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers tJuly 3, 2024 | marketbeat.comInventiva S.A. (NASDAQ:IVA) Short Interest Up 68.9% in JuneInventiva S.A. (NASDAQ:IVA - Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 116,200 shares, a growth of 68.9% from the May 31st total of 68,800 shares. Based on an average trading volume of 19,200 shares, the days-to-cover ratio is presently 6.1 days.June 30, 2024 | marketbeat.comResults of the votes of the Combined Shareholders' General Meeting of June 20, 2024June 21, 2024 | globenewswire.comInventiva S.A. (NASDAQ:IVA) Receives Average Recommendation of "Buy" from AnalystsInventiva S.A. (NASDAQ:IVA - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokJune 8, 2024 | marketbeat.comInventiva (NASDAQ:IVA) Stock Price Down 5.1%Inventiva (NASDAQ:IVA) Stock Price Down 5.1%June 5, 2024 | marketbeat.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 30, 2024 | globenewswire.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 28, 2024 | seekingalpha.com Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. IVA Media Mentions By Week IVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.360.46▲Average Medical News Sentiment IVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼82▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANNX News Today SANA News Today GHRS News Today ORGO News Today ATXS News Today PRTC News Today CRVS News Today GLUE News Today MREO News Today PROK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IVA Stock Alerts